AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 51 min read$ELVN

Garland J. Scott sold $607K of ELVN

Garland J. Scott sold 13,000 shares of Enliven Therapeutics, Inc. (ELVN) at $46.67 ($0.61M total) on 2026-10-01.

Original reporting
SEC EDGAR · Garland J. Scott
Published Oct 5, 2026, 8:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 8:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ELVN
Bearish
medium confidence
Mentioned
$ELVN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ELVNBearishLow
01

Why it matters

The market may view the sale as a negative signal, but the modest dollar amount limits broader impact.

02

Market read

Primary relevance is to ELVN shareholders; negligible effect on sector or market.

03

What to watch

Potential upcoming clinical data or financing needs not disclosed in the filing.

Relevance 5/10Novelty 4/10Timing: after-hours filing

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the director's complete exit.

Company-level read

Ticker impact

$ELVNBearishMedium confidence
Context

Director Garland J. Scott sold his entire 13,000 shares for $606,719, reducing his stake to zero.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A director exiting completely suggests lack of confidence; the transaction size is modest but notable for a micro‑cap.

Market effects

Sector

Minimal impact on the broader biotech sector; isolated insider activity.

Regional

Limited to U.S. markets where ELVN trades.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to fundamentals.

Key entities

  • Director
    Garland J. Scott

    Director of Enliven Therapeutics who sold all holdings.

  • Company
    Enliven Therapeutics, Inc.

    Biotech firm listed on NASDAQ under ticker ELVN.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ELVN insider trading history →

Related articles

OCT 8
$ELVNMedAI 8/10

Guggenheim reiterates Enliven Therapeutics stock rating on FDA alignment

Guggenheim reiterated a Buy rating and $78 price target for Enliven Therapeutics (ELVN) after FDA alignment on its Phase 3 study design for relcobatinib. The stock is down 10.5% this week but up 169% YTD. Multiple analysts have initiated coverage with positive ratings and price targets ranging from $70 to $78. The Phase 3 trial will enroll 450 patients and is set to start by year-end 2026.

investing.com2 min
OCT 6
$ELVNMedAI 8/10

Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia

Enliven Therapeutics (ELVN) reached FDA agreement on the Phase 3 trial design for relcobatinib (ELVN-001) in treating chronic myeloid leukemia. The ENABLE-2 trial will compare relcobatinib to second-generation TKIs, with a target enrollment of 450 patients. The company plans to initiate the trial by year-end 2026.

prnewswire.com2 min
OCT 1
$ELVNMed

Enliven Therapeutics stock initiated at Overweight by JPMorgan

JPMorgan initiated coverage on Enliven Therapeutics (ELVN) with an Overweight rating and a $75 price target, implying 64% upside. The stock has surged 198% year-to-date. Analysts highlight ELVN-001's potential in treating chronic-phase CML, with U.S. peak sales estimated at $5 billion. Recent reports from William Blair, Barclays, and Guggenheim also show positive outlooks.

investing.com2 min